AR070236A1 - Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuesto - Google Patents
Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuestoInfo
- Publication number
- AR070236A1 AR070236A1 ARP090100205A ARP090100205A AR070236A1 AR 070236 A1 AR070236 A1 AR 070236A1 AR P090100205 A ARP090100205 A AR P090100205A AR P090100205 A ARP090100205 A AR P090100205A AR 070236 A1 AR070236 A1 AR 070236A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrimidin
- oxo
- methyl
- acid
- enantiomerically pure
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000013160 medical therapy Methods 0.000 title abstract 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 title 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003906 phosphoinositides Chemical class 0.000 abstract 2
- -1 7-methyl-2- (morpholin-4-yl) -4-oxo-4H-pyrido [1,2-a] pyrimidin-9-yl Chemical group 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000001835 viscera Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a ácido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4H-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro o a sales farmacéuticamente aceptables del mismo, estando éste en estado solido, a su uso en terapia médica, a una composicion farmacéutica que lo comprende, a su uso en la preparacion de un medicamento para utilizar en un método para prevenir o tratar enfermedades, y a su uso en un método para prevenir o tratar enfermedades. La presente se refiere a un inhibidor selectivo de la fosfoinositide (Pl) 3-quinasa beta y al uso del inhibidor selectivo por ejemplo en la terapia antitrombotica. Estos compuestos son utiles para tratar trombos plaquetarios, ataques isquémicos, angina inestable e isquemia aguda de extremidades y organos internos. Reivindicacion 7: El enantiomero puro de acuerdo con cualquiera de las reivindicaciones 1 a 6, que se caracteriza por tener picos de XRPD en los siguientes valores d aproximados: 6,8; 5,9 y 3,91 L. Reivindicacion 8: El enantiomero puro de acuerdo con cualquiera de las reivindicaciones 1 a 6, que se caracteriza por tener picos de XRPD en los siguientes valores d aproximados: 6,8; 6,1; 5,9; 4,98; 4,41; 4,26 y 3,91 L. Reivindicacion 9: Ácido (-) 2-[(1R)-1-(7-metil-2-(morfolin-4-il)-4-oxo-4H-pirido[1,2- a]pirimidin-9-il]etilamino]benzoico de acuerdo con la reivindicacion 7 o con la reivindicacion 8 que se caracteriza por tener un difractograma de XRPD esencialmente segun se muestra en la FIGURA 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2349808P | 2008-01-25 | 2008-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070236A1 true AR070236A1 (es) | 2010-03-25 |
Family
ID=40899463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100205A AR070236A1 (es) | 2008-01-25 | 2009-01-23 | Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuesto |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090191177A1 (es) |
| EP (1) | EP2245030A4 (es) |
| JP (1) | JP2011510071A (es) |
| KR (1) | KR20100118977A (es) |
| CN (1) | CN101925601A (es) |
| AR (1) | AR070236A1 (es) |
| AU (1) | AU2009206804A1 (es) |
| BR (1) | BRPI0906805A2 (es) |
| CA (1) | CA2712022A1 (es) |
| CL (1) | CL2009000148A1 (es) |
| MX (1) | MX2010008097A (es) |
| PE (1) | PE20091402A1 (es) |
| RU (1) | RU2010133715A (es) |
| TW (1) | TW200936138A (es) |
| UY (1) | UY31609A1 (es) |
| WO (1) | WO2009093972A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| DK2655375T3 (en) * | 2010-12-23 | 2015-03-09 | Sanofi Sa | PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF |
| FR2969613B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| CN104592222B (zh) * | 2014-12-26 | 2016-08-24 | 苏州明锐医药科技有限公司 | 抗血小板药物azd6482的制备方法 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| CA3177787A1 (en) * | 2020-05-14 | 2021-11-18 | Shaun Jackson | Treatment of thrombosis and associated disorders with an anti-platelet agent. |
| IL307950A (en) | 2021-05-03 | 2023-12-01 | Petra Pharma Corp | Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases |
| MX2023013987A (es) | 2021-05-27 | 2024-02-12 | Petra Pharma Corp | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer. |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| US20250084048A1 (en) * | 2021-10-07 | 2025-03-13 | Relay Therapeutics, Inc. | Pi3k-alpha inhibitors and methods of use thereof |
| WO2023081209A1 (en) * | 2021-11-03 | 2023-05-11 | Zeno Management, Inc. | Pi3k inhibitors and methods of treating cancer |
| WO2023159155A1 (en) * | 2022-02-18 | 2023-08-24 | Pivalent Therapeutics, Inc. | Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof |
| US20250263394A1 (en) * | 2022-04-24 | 2025-08-21 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2024051778A1 (en) * | 2022-09-09 | 2024-03-14 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| EP4602043A1 (en) * | 2022-10-14 | 2025-08-20 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
| WO2024099437A1 (en) * | 2022-11-11 | 2024-05-16 | Fochon Biosciences, Ltd. | Compounds as protein kinase inhibitors |
| WO2024151759A1 (en) * | 2023-01-11 | 2024-07-18 | Synnovation Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS |
| EP4731625A1 (en) * | 2023-06-23 | 2026-04-29 | The Heart Research Institute Ltd | New synthesis method |
| WO2026013052A1 (en) * | 2024-07-09 | 2026-01-15 | Institut National de la Santé et de la Recherche Médicale | Methods of treating familial adenomatous polyposis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05509302A (ja) * | 1990-06-20 | 1993-12-22 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類 |
| EP1857443B1 (en) * | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| JP4646626B2 (ja) * | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
-
2009
- 2009-01-22 KR KR1020107017149A patent/KR20100118977A/ko not_active Withdrawn
- 2009-01-22 AU AU2009206804A patent/AU2009206804A1/en not_active Abandoned
- 2009-01-22 BR BRPI0906805-8A patent/BRPI0906805A2/pt not_active IP Right Cessation
- 2009-01-22 MX MX2010008097A patent/MX2010008097A/es not_active Application Discontinuation
- 2009-01-22 CA CA2712022A patent/CA2712022A1/en not_active Abandoned
- 2009-01-22 WO PCT/SE2009/050065 patent/WO2009093972A1/en not_active Ceased
- 2009-01-22 JP JP2010544271A patent/JP2011510071A/ja active Pending
- 2009-01-22 CN CN2009801035429A patent/CN101925601A/zh active Pending
- 2009-01-22 EP EP09703707A patent/EP2245030A4/en not_active Withdrawn
- 2009-01-22 RU RU2010133715/04A patent/RU2010133715A/ru not_active Application Discontinuation
- 2009-01-23 CL CL2009000148A patent/CL2009000148A1/es unknown
- 2009-01-23 AR ARP090100205A patent/AR070236A1/es unknown
- 2009-01-23 UY UY031609A patent/UY31609A1/es unknown
- 2009-01-23 PE PE2009000099A patent/PE20091402A1/es not_active Application Discontinuation
- 2009-01-23 TW TW098103073A patent/TW200936138A/zh unknown
- 2009-01-25 US US12/359,323 patent/US20090191177A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2245030A1 (en) | 2010-11-03 |
| CN101925601A (zh) | 2010-12-22 |
| BRPI0906805A2 (pt) | 2015-07-14 |
| RU2010133715A (ru) | 2012-02-27 |
| WO2009093972A1 (en) | 2009-07-30 |
| AU2009206804A1 (en) | 2009-07-30 |
| KR20100118977A (ko) | 2010-11-08 |
| EP2245030A4 (en) | 2012-03-21 |
| PE20091402A1 (es) | 2009-10-21 |
| JP2011510071A (ja) | 2011-03-31 |
| UY31609A1 (es) | 2009-08-31 |
| CL2009000148A1 (es) | 2010-10-15 |
| TW200936138A (en) | 2009-09-01 |
| MX2010008097A (es) | 2010-08-04 |
| CA2712022A1 (en) | 2009-01-30 |
| US20090191177A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070236A1 (es) | Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuesto | |
| UY39786A (es) | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| CL2020000283A1 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak. | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| EA201000130A1 (ru) | Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| EA201100698A1 (ru) | Производные тиенотриазолодиазепина, активные в отношении апо а1 | |
| WO2006110917A3 (en) | Spiro-oxindole compounds and their uses as therapeutic agents | |
| NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
| AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| BR112021022255A2 (pt) | Composto usado como inibidor de quinase e aplicação do mesmo | |
| PY2018921A (es) | Agentes antiproliferativos para el tratamiento de pah | |
| AR058904A1 (es) | Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo | |
| SA519401614B1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| UY31813A (es) | Compuestos de pirazina fusionados útiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| MX2022016497A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica. | |
| AR068439A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |